Cochlear announces earnings upgrade
Wednesday, 14 December, 2005
Bionic ear specialist Cochlear (ASX:COH) has announced an upgrade of its guidance on core earnings for the 2005-06 financial year to AUD$80 million.
The company gave previous guidance that its core earnings for the year would increase by 20 per cent from 2005 financial year levels to about $70 million. Stronger sales could now lead to an increase of 37 per cent over the last year, the company said, with core earnings in the order of $80 million.
"Sales momentum, which picked up the second half of the last financial year, has continued to be stronger than predicted, particularly from the new Nucleus Freedom Cochlear Implant System released from April 2005," said Cochlear CEO Chris Roberts in a statement.
The company will provide further details of its first half results on February 14, 2006.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
